Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
BHVNApril 28, 2025
Read more →Baird Maintains Outperform on Biohaven, Lowers Price Target to $57
BHVNApril 28, 2025
Read more →Biohaven Announces $600M Non-Dilutive Funding Agreement With Oberland Capital To Advance Rare Disease Portfolio
BHVNApril 28, 2025
Read more →'Biohaven Withdraws Initial Marketing Authorization Application For Dazluma' - European Medical Agency
BHVNApril 25, 2025
Read more →Reported Saturday, Biohaven Presents At AAN 2025: 13 Abstracts Reflect Progress On Novel CNS Therapies Targeting High-Unmet-Need Neurological Disorders
BHVNApril 7, 2025
Read more →Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $63
BHVNMarch 7, 2025
Read more →JP Morgan Maintains Overweight on Biohaven, Lowers Price Target to $68
BHVNMarch 5, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $54 Price Target
BHVNMarch 4, 2025
Read more →RBC Capital Reiterates Outperform on Biohaven, Maintains $61 Price Target
BHVNMarch 4, 2025
Read more →Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
BHVNBiohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.
March 3, 2025
Read more →Biohaven Says Data From Phase 1 Of BHV-1300 Shows Rapid And Deep Reductions In Total IgG, For The Potential Treatment Of Autoimmune Disease
BHVNMarch 3, 2025
Read more →What's Going On With Merus Stock Monday?
BHVNMerus announced a research collaboration and license agreement with Biohaven.
January 13, 2025
Read more →Biohaven Highlights Phase 1 Data For BHV-1400 In IgA Nephropathy With 70% Reduction In Target Antibody. Advances Include BHV-1600 For PPCM And BHV-1300 For Graves' Disease. Multiple Trials Set For 2025
BHVNJanuary 13, 2025
Read more →Reported Earlier, Merus And Biohaven Partner to Co-Develop Three Novel Bispecific Antibody Drug Conjugate (ADC) Programs
BHVNJanuary 13, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
BHVNNovember 14, 2024
Read more →This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
BHVNThe Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
May 22, 2024
Read more →